| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Rein Therapeutics, Inc.$0.98
-0.02 (-1.78%)
D 25Pipeline Score Richly Valued Pharma · Clinical
Market Cap
88.11 M
EPS
-1.91
P/E Ratio
-
Value Trade
411.30 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
3.07 M
Operating CF
-3.42 M
Total Assets
26.29 M
Total Liabilities
14.70 M
Equity
11.59 M
D/E Ratio
12,345
-6.36 %
Week
-46.07 %
1 Month
-5.5 %
3 Month
-26.43 %
6 Month
-99.79 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
4.45 M
Monthly Burn
1.14 M
Runway
2.3 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
148.43 K
52 Week Range
0.95 - 2.21
% held by Insiders
7.69 %
% held by Institutions
22.24 %
Enterprise Value
133.59 M
Total Shares
26.29 M
Short %
3.99 %
Float Shares
22.50 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rein Therapeutics, Inc.
90Total events
2Upcoming
21Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 2
Event history 88
Q3 2026
◆Topline ReadoutLTI-03Clinical Data
Initial topline data expected in Q3 2026
idiopathic pulmonary fibrosissource ↗
Jun 11, 2026
◆Enrollment UpdateLTI-03Trial
16 patients enrolled to date in Phase 2 RENEW trial
idiopathic pulmonary fibrosissource ↗
Jun 11, 2026
▲First Patient DosedLTI-03Trial
First patient randomized in the United Kingdom
idiopathic pulmonary fibrosissource ↗
May 18, 2026
▼Equity OfferingCorporate
Closing of $57.5 million underwritten public offering of common stock, including full exercise of over-allotment option
Apr 30, 2026
▼Equity OfferingCorporate
Pricing of $50 million underwritten public offering of common stock at $1.00 per share
Apr 29, 2026
◆Enrollment UpdateLTI-03Trial
2 additional patients expected to be enrolled this week
idiopathic pulmonary fibrosissource ↗
Apr 29, 2026
▲Trial InitiationLTI-03Trial
Clinical trial sites active in US, Australia, Poland; UK and Germany expected to open
idiopathic pulmonary fibrosissource ↗
Mar 3, 2026
▲First Patient DosedLTI-03Trial
First patient dosed in Phase 2 trial of LTI-03 for IPF
idiopathic pulmonary fibrosissource ↗
Mar 3, 2026
▲IND ClearanceLTI-03IND
FDA clearance to resume Phase 2 program for LTI-03
idiopathic pulmonary fibrosissource ↗
Mar 2026
▲Enrollment MilestoneLTI-03Trial
Enrollment initiated in March 2026
idiopathic pulmonary fibrosissource ↗
Jan 20, 2026
▲EMA OrphanLTI-03Ex-US Regulatory
EMA orphan drug designation for LTI-03 in IPF
idiopathic pulmonary fibrosissource ↗
Q1 2026
◆Topline ReadoutLTI-03Clinical Data
Topline interim data from RENEW Phase 2 trial expected
idiopathic pulmonary fibrosissource ↗
Drug Pipeline Intelligence
D25
Pipeline Score $13M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 24%
Micro Cap (rank 693 of 911)
Percentile RankRein Therapeutics, Inc. faces pipeline headwinds (25/100), with $555M risk-adjusted pipeline value, led by Nivolumab in Metastatic Kidney Cancer (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nivolumab Small molecule | Metastatic Kidney Cancer | Phase 3 | NCT06364631 | 46% | $408M | RECRUITING | 1,250 | - | - | May 5, 2032 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LTI-03 Orphan | idiopathic pulmonary fibrosis | Phase 2 | 2025-11-06 | LTI-03 was generally well tolerated, and samples collected from treated patients showed reductions in multiple fibrosis-associated biomarkers. Read More | Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF Read More | |
LTI-03 Orphan | idiopathic pulmonary fibrosis | Phase 2 | 2025-11-06 | LTI-03 was generally well tolerated, and samples collected from treated patients showed reductions in multiple fibrosis-associated biomarkers. Read More | Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF Read More | |
LTI-03 Orphan | idiopathic pulmonary fibrosis | Phase 2 | 2025-11-06 | LTI-03 was generally well tolerated, and samples collected from treated patients showed reductions in multiple fibrosis-associated biomarkers. Read More | Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RNTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RNTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RNTXRein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
Rein Therapeutics has expanded its Phase 2 RENEW trial for LTI-03 into the UK, marking a significant milestone with the first patient randomized. The trial, which targets idiopathic pulmonary fibrosis, has enrolled 16 patients so far and is actively recruiting in the US, Australia, and the UK, with plans to include more countries. The study aims to assess the safety and efficacy of LTI-03, a novel inhaled peptide therapy.
Read more →RNTXRein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rein Therapeutics has successfully closed a $57.5 million underwritten public offering, which included the full exercise of the over-allotment option. The proceeds will fund the ongoing Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) and support operations until 2028. The offering attracted both new and existing healthcare-focused investors.
Read more →RNTX▼ -24%on this news
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rein Therapeutics has announced the pricing of a $50 million underwritten public offering of common stock at $1.00 per share. The offering aims to fund the ongoing Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis and support general corporate purposes. The closing is expected around May 4, 2026, pending customary conditions.
Read more →RNTX▼ -12.1%on this news· ran to -30% by day 3shared move
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has provided an update about its Phase 2 RENEW clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF). Currently, 8 patients have been enrolled, with expectations for more as the trial continues to expand across sites in the United States, Australia, and Poland. The study aims to evaluate LTI-03's safety and efficacy in approximately 120 patients, with promising early data suggesting its dual-action capability in treating fibrosis and aiding lung healing. CEO Brian Windsor highlighted the ongoing efforts of clinical teams in progressing the trial.
Read more →RNTXRein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
Rein Therapeutics has initiated its Phase 2 clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF). The trial, which follows FDA clearance, aims to evaluate the safety and efficacy of LTI-03 in approximately 120 patients across multiple countries. Interim data is expected in the latter half of 2026, marking a significant step in addressing the unmet medical needs of IPF patients.
Read more →RNTXRein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has been granted orphan drug designation by the European Medicines Agency for its lead drug candidate LTI-03, aimed at treating idiopathic pulmonary fibrosis (IPF). This designation acknowledges the serious nature of IPF and the need for new therapies. The decision was based on promising preclinical data indicating improved survival and lung function. The designation also provides regulatory incentives to facilitate further development.
Read more →RNTXRein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
Rein Therapeutics announced a new preprint detailing the results of a dose-escalation study of LTI-03 in idiopathic pulmonary fibrosis (IPF). The study found that LTI-03 was well tolerated and reduced fibrosis-associated biomarkers while preserving vital lung cells. The findings support LTI-03's potential as a differentiated therapy for IPF, prompting the advancement of the drug into Phase 2 trials.
Read more →RNTX▲ +11.8%on this newsshared move
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has received FDA clearance to resume its Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) after addressing the agency's concerns. The trial, named 'RENEW', will involve approximately 20 U.S. sites and aims to evaluate the drug's safety and efficacy. Initial topline data is anticipated in Q3 2026, marking a significant step forward for the company's development program.
Read more →RNTXRein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has received European regulatory approval to initiate its Phase 2 'RENEW' trial for LTI-03, targeting idiopathic pulmonary fibrosis. The trial will take place in Germany and Poland, following prior clearance from the UK. The study aims to evaluate the safety and efficacy of LTI-03, which has a dual mechanism to combat fibrosis and support lung tissue regeneration.
Read more →RNTXRein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
Rein Therapeutics announced the publication of new data on its drug candidate LTI-03, demonstrating anti-fibrotic activity in lung tissue from IPF patients. The findings support the ongoing Phase 2 RENEW trial, which aims to evaluate LTI-03's safety and efficacy. The urgent need for effective treatments in IPF is emphasized by the disease's high mortality rate and limited current options.
Read more →RNTXRein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has received U.K. regulatory approval to commence its Phase 2 clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF). This trial, named "RENEW," will assess the safety and tolerability of LTI-03 in up to 120 patients worldwide. The company's lead drug candidate aims to directly target lung fibrosis and has the potential to significantly improve patient outcomes. Initial data from the trial is expected in 2026, with patient recruitment beginning shortly in the U.K.
Read more →RNTXRein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rein Therapeutics will present at the IPF Summit 2025, showcasing insights into idiopathic pulmonary fibrosis (IPF) treatment. Chief Scientific Officer Cory Hogaboam will discuss biological processes in IPF, while CEO Brian Windsor will share lessons from clinical trials. The summit aims to advance understanding and treatment of IPF.
Read more →RNTXRein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing
Rein Therapeutics has entered into financing agreements with Yorkville Advisors, potentially granting access to $21 million. This funding will primarily support the RENEW Phase 2 trial for LTI-03, aimed at treating idiopathic pulmonary fibrosis, alongside other corporate needs. The company emphasizes its commitment to developing innovative therapies for orphan diseases.
Read more →RNTXRein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Rein Therapeutics announced the adjournment of its 2025 annual meeting due to a lack of quorum. The meeting will reconvene on July 23, 2025, allowing stockholders more time to vote on proposals. The company continues to encourage participation from stockholders who have not yet voted.
Read more →RNTXRein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics has announced the dosing of the first patient in the RENEW Phase 2 trial for LTI-03, aimed at treating idiopathic pulmonary fibrosis (IPF). The trial will evaluate the drug's safety, tolerability, and efficacy, with interim data expected in the first half of 2026. Rein is collaborating with IQVIA for patient enrollment across multiple sites globally.
Read more →RNTX▼ -10.2%on this news
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
Rein Therapeutics presented two posters at the ATS 2025 International Conference, highlighting the potential of LTI-03 in treating idiopathic pulmonary fibrosis (IPF). The presentations emphasized LTI-03's dual mechanism, showcasing its ability to promote alveolar epithelial cell survival and inhibit profibrotic signaling. The company has initiated the RENEW Phase 2 trial to further evaluate LTI-03's efficacy and safety in IPF patients.
Read more →RNTX▼ -6.4%on this news· ran to -18% by day 3shared move
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Rein Therapeutics has reported its first quarter 2025 financial results and announced the initiation of the Phase 2 RENEW trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF). The company has extended its cash runway through recent financial transactions and is collaborating with Qureight to enhance its clinical trial processes. Topline interim data from the trial is expected in the first half of 2026.
Read more →RNTXRein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics has announced the initiation of its RENEW Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) using LTI-03. The trial is set to enroll up to 120 patients across multiple international sites, following promising results from prior Phase 1b studies. This randomized, double-blind, placebo-controlled study aims to evaluate LTI-03's safety and efficacy while assessing various lung function biomarkers. Topline data from the trial is expected in the first half of 2026.
Read more →RNTXRein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics announced a collaboration with Qureight Ltd to integrate their deep-learning platform into the upcoming Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF). This partnership aims to enhance the analysis of lung imaging data and improve trial workflows. Rein has previously reported positive results from a Phase 1b trial, with plans to provide further trial details soon. The collaboration is expected to deliver more precise insights into LTI-03's therapeutic effects on lung function.
Read more →RNTXRein Therapeutics to Present at The Citizens Life Sciences Conference 2025
Rein Therapeutics will present at The Citizens Life Sciences Conference 2025 on May 8, 2025. CEO Brian Windsor will discuss their novel therapies targeting orphan pulmonary and fibrosis conditions. The company is preparing to initiate a Phase 2 trial for their lead candidate, LTI-03, in idiopathic pulmonary fibrosis. Additionally, LTI-01 has received Orphan Drug and Fast Track Designations.
Read more →RNTX▼ -7.9%on this newsshared move
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
Rein Therapeutics announced that an abstract has been accepted for presentation at the American Thoracic Society 2025 International Conference. The presentation will focus on the regenerative properties of Caveolin Scaffolding Peptides in lung samples. The conference is scheduled for May 18-21, 2025, in San Francisco, CA.
Read more →RNTXRein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
Rein Therapeutics has been granted two patents for its lead product candidate, LTI-03, which is a synthetic peptide designed for dry powder inhalation to treat various lung diseases. The patents strengthen the company's position in the market and support the upcoming Phase 2 clinical trial for idiopathic pulmonary fibrosis. The dual mechanism of LTI-03 aims to address unmet medical needs in pulmonary conditions.
Read more →RNTXRein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
Rein Therapeutics announced a publication in the journal Biomedicines detailing the effects of the Caveolin-1-related peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F). The study shows that LTI-2355 enhances the phagocytic activity of myeloid cells while reducing their pro-inflammatory and pro-fibrotic activities. This publication underscores the potential of CSD peptides in treating fibrotic conditions.
Read more →RNTXRein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rein Therapeutics, Inc. has reported its fourth quarter and full year 2024 financial results, highlighting significant clinical progress with its lead asset, LTI-03, for idiopathic pulmonary fibrosis (IPF). Positive topline results from a Phase 1b trial indicate potential therapeutic effects, prompting plans to initiate a Phase 2 trial in the first half of 2025. However, the company reported a substantial net loss for the quarter, mainly attributed to a non-cash impairment charge, alongside a decreased cash position year over year.
Read more →RNTXAileron Therapeutics Announces Rebranding to Rein Therapeutics
Aileron Therapeutics has rebranded to Rein Therapeutics, focusing on therapies for orphan pulmonary and fibrosis conditions. The company's stock will trade under the new ticker RNTX from January 13, 2025. Rein’s lead candidate, LTI-03, is set to enter a Phase 2 clinical trial following positive top-line data from previous phases. The company aims to advance its pipeline of first-in-class treatments for conditions like idiopathic pulmonary fibrosis, marking a significant reaffirmation of its therapeutic mission.
Read more →RNTXAileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in
Aileron Therapeutics has reported its financial results for Q3 2024, highlighting significant progress in its Phase 1b clinical trial for LTI-03, a treatment for idiopathic pulmonary fibrosis. Positive safety and biomarker data from Cohort 2 (5mg BID) demonstrated dose-dependent effects across five biomarkers, with statistical significance in four when combining data from both cohorts. The company is now planning a Phase 2 clinical trial, signaling optimism about the drug's potential. Despite the encouraging results, further clinical developments will be necessary to confirm efficacy and safety in ongoing trials.
Read more →RNTXAileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in
Aileron Therapeutics reported its second quarter 2024 financial results, highlighting positive data from the ongoing Phase 1b trial of LTI-03 in idiopathic pulmonary fibrosis. The results indicated statistical significance in three out of eight biomarkers evaluated in the first cohort. The company raised approximately $18.2 million to support further development of LTI-03, with topline results for the high-dose cohort expected in the third quarter. Despite a reported net loss of $8,942 thousand, the company is focused on advancing its clinical programs.
Read more →RNTXAileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Aileron Therapeutics reported positive results from Cohort 1 of its Phase 1b trial for LTI-03 in idiopathic pulmonary fibrosis, showing statistical significance in three biomarkers. The company anticipates topline results from Cohort 2 in Q3 2024. Despite progress, there are risks regarding patient enrollment and maintaining financial stability.
Read more →RNTXAileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics will present at two investor conferences in May 2024. CEO Brian Windsor will speak at the Citizens JMP Life Sciences Conference on May 13 and the H.C. Wainwright BioConnect Investor Conference on May 20. The company is advancing treatments for orphan pulmonary and fibrosis indications, with ongoing clinical trials for its lead product candidate, LTI-03.
Read more →RNTXAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron Therapeutics announced the successful closing of a $20 million underwritten registered direct offering. The offering involved 4,273,505 shares of common stock and accompanying warrants. Proceeds will support Aileron's development of innovative treatments for orphan pulmonary and fibrosis indications, including their lead product candidate, LTI-03, currently in Phase 1b trials.
Read more →RNTXAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well
Aileron Therapeutics has announced a priced underwritten registered direct offering expected to raise up to approximately $40 million. The initial funding amount is estimated at $20 million, with potential for an additional $20 million from warrant exercises. The offering includes 4,273,505 shares of common stock, priced at $4.68 each, and is set to close on May 3, 2024, pending customary conditions. This funding will support Aileron's clinical pipeline, particularly its lead candidate, LTI-03, for idiopathic pulmonary fibrosis.
Read more →RNTXAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treat
Aileron Therapeutics reported its financial results for the fourth quarter and full year of 2023, highlighting a strong cash position and successful merger with Lung Therapeutics. The company's lead product candidate, LTI-03, is being developed for idiopathic pulmonary fibrosis, with topline Phase 1b results expected by Q3 2024. While the financials indicate a sizable net loss, the promising potential of LTI-03 and its dual mechanism of action have garnered support within the medical community. Aileron anticipates 2024 as a pivotal year for advancing its clinical programs.
Read more →RNTXAileron Therapeutics Announces CEO Transition Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipel
Aileron Therapeutics has announced a leadership transition, appointing Brian Windsor, Ph.D., as the new Chief Executive Officer. Windsor, previously the President and COO, will lead the company in its mission to advance a pipeline of innovative therapies for orphan pulmonary and fibrosis diseases. This change comes after the company’s acquisition of Lung Therapeutics, Inc., and follows the stepping down of former CEO Manuel Aivado, who will remain on the Board of Directors. The transition emphasizes the firm's strategic focus on developing promising treatments like LTI-03 and LTI-01.
Read more →RNTXAileron Therapeutics Announces Acquisition of Lung Therapeutics Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the tre
Aileron Therapeutics has completed the acquisition of Lung Therapeutics, which focuses on therapies for orphan pulmonary diseases, including the candidate LTI-03. The acquisition is expected to enhance Aileron's clinical pipeline and create value for stakeholders. A private placement is anticipated to raise around $18 million to fund the Phase 1b clinical study of LTI-03 for idiopathic pulmonary fibrosis and support corporate activities. The management team will remain in place post-acquisition to drive future development efforts.
Read more →RNTXAILERON THERAPEUTICS, INC. 2021 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2021 Stock Incentive Plan (the Plan ) of Aileron Therapeutics, Inc., a Delaware corporation (the Company ), is to advance the interests
AILERON THERAPEUTICS, INC. 2021 STOCK INCENTIVE PLAN The purpose of this 2021 Stock Incentive Plan (the Plan ) of Aileron Therapeutics, Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by enhancing the Company s ability to
Read more →RNTXAileron Therapeutics Announces $35.9 Million Registered Direct Offering
Aileron Therapeutics Announces $35.9 Million Registered Direct Offering WATERTOWN, Mass., January 6, 2021 (GLOBE NEWSWIRE) Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for the pur
Read more →RNTXPrevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924 Zoran Andric1, Timur Ceric2, Mirko Stanetic3, Milan Rancic4, Marko Jakopovic5, Santiago Ponce Aix6,
Prevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924 Zoran Andric1, Timur Ceric2, Mirko Stanetic3, Milan Rancic4, Marko Jakopovic5, Santiago Ponce Aix6, Rodryg Ramlau7, Egbert Smit8, Malgorzata Ulanska9, Christo
Read more →RNTXAileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital WATERTOWN, Mass., September 21, 2020 Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement ( Purchase Agreem
Read more →RNTXAileron Therapeutics Announces Pricing of Public Offering of Common Stock
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock WATERTOWN, Mass., June 4, 2020 (GLOBE NEWSWIRE) Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offer
Read more →RNTXALRN-6924: Ongoing Ph1b Clinical Trial in Small Cell Lung Cancer Patients Receiving Topotecan Dose Optimization N = 18 ALRN-6924 24h before topotecan 3 dose levels tested Expansion commenced Schedule Optimization N = 20
Interim data from Phase 1b dose optimization trial Exhibit 99.1 ALRN-6924: Ongoing Ph1b Clinical Trial in Small Cell Lung Cancer Patients Receiving Topotecan Dose Optimization N = 18 ALRN-6924 24h before topotecan 3 dose levels tested Expansion commenced Schedule Optimization
Read more →RNTXAileron Therapeutics Announces Management Change Watertown, Mass.
Aileron Therapeutics Announces Management Change Watertown, Mass., September 9, 2019 Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Don Dougherty, its cu
Read more →RNTXAileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach WATERTOWN, Mass., June 24, 2019 (GLOBE NEWSWIRE) Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating pepti
Read more →RNTXAileron Therapeutics Completes $26M Private Placement Satter Medical Technology Partners led the private placement; Dr. Nolan Sigal, Partner at Satter Management, joins Aileron s Board of Directors Watertown, Mass.
Aileron Therapeutics Completes $26M Private Placement Satter Medical Technology Partners led the private placement; Dr. Nolan Sigal, Partner at Satter Management, joins Aileron s Board of Directors Watertown, Mass., April 3, 2019 (GLOBE NEWSWIRE) Aileron Therapeutics (NASDAQ:
Read more →RNTXAileron Therapeutics Announces Pricing of $26M Private Placement
Aileron Therapeutics Announces Pricing of $26M Private Placement WATERTOWN, Mass., March 29, 2019 (GLOBE NEWSWIRE) Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, announced to
Read more →RNTXAileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer WATERTOWN, Mass., September 6, 2018 Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today a
Read more →RNTXAileron Therapeutics Announces Changes to Management CAMBRIDGE, MA
Aileron Therapeutics Announces Changes to Management CAMBRIDGE, MA May 15, 2018 Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Joseph A. Yanchik III has resigned as
Read more →RNTXAileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors CAMBRIDGE, Mass., March 19, 2018 Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced the
Read more →Competitive Position
How RNTX ranks across every disease it competes inCompetitive Position is a premium feature
See how RNTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial